Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 8,600 shares, a drop of 18.1% from the June 15th total of 10,500 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily trading volume, of 4,400 shares, the short-interest ratio is currently 2.0 days.

Xenetic Biosciences Price Performance

XBIO stock opened at $4.08 on Monday. Xenetic Biosciences has a 1-year low of $2.87 and a 1-year high of $5.97. The business has a 50-day moving average price of $3.94 and a 200 day moving average price of $3.92. The company has a market capitalization of $6.29 million, a P/E ratio of -1.39 and a beta of 2.28.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.01. Xenetic Biosciences had a negative net margin of 182.99% and a negative return on equity of 43.40%. The business had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.65 million. On average, analysts anticipate that Xenetic Biosciences will post -0.96 earnings per share for the current fiscal year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.